Screener
Ocular Therapeutix OCUL Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Net cash used in investing activities | (4,662) | (1,933) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 294 | 4,183 |
| Net cash provided by financing activities | 294 | 4,183 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (70,361) | (42,421) |
| Cash, cash equivalents and restricted cash at beginning of period | 738,674 | 393,716 |
| Cash, cash equivalents and restricted cash at end of period | $668,313 | $351,295 |
| Supplemental disclosure of cash flow information: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's financing cash flow?
- Ocular Therapeutix (OCUL) reported financing cash flow of $294K in Q1 2026.
- How has Ocular Therapeutix's financing cash flow changed year-over-year?
- Ocular Therapeutix's financing cash flow decreased by 93.0% year-over-year, from $4.18M to $294K.
- What is the long-term trend for Ocular Therapeutix's financing cash flow?
- Over 4 years (2021 to 2025), Ocular Therapeutix's financing cash flow has grown at a 274.7% compound annual growth rate (CAGR), from $2.85M to $561.72M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Ocular Therapeutix's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude